Gilead's $32B U.S. investment is fueling American science — and innovation. At Gilead, we strive to create a healthier world for all people.

Gilead invests in world-class science and is pursuing innovation across the therapeutic areas of virology, oncology and inflammation.

• Gilead is investing $32 billion in the U.S. through 2030 to expand research, manufacturing and workforce infrastructure as part of a broader global strategy to deliver scientific breakthroughs where they can have the greatest impact.

The idea: Biopharmaceutical innovation can't happen without infrastructure. Gilead's expansion strategy helps ensure transformative medicines are discovered and delivered at home — while reinforcing the global pipeline that supports patients around the world.

• "Our U.S. investment strategy reflects a simple belief: that the future of medicine should be built here," said Daniel O'Day, Chairman and CEO of Gilead Sciences. "By strengthening our American footprint as part of a global innovation engine, we're helping ensure patients everywhere benefit from our world-class therapies."

The strategy: Gilead's U.S. investment includes:

• Investing in AI-enabled labs and advanced manufacturing sites.
• Creating over 3,000 direct and supported jobs.
• Expanding capacity for personalized therapies and large-scale production.

These efforts are designed to speed access to innovation, build supply chain resilience and redefine what's possible in medicine.

Key numbers:

• 98% of Gilead's R&D infrastructure is U.S.-based.
• 80%+ of profits are reinvested in the U.S.
• $43B in projected U.S. economic impact.

Investing in our promise

Since 2017, Gilead has added more than 16,000 high-quality U.S. jobs, with over 70% of domestic employees focused on R&D. New investments are fueling advanced treatments in virology, inflammation and cancer.

At Gilead, every investment begins with people and ends with purpose. Our commitment to expanding U.S. infrastructure goes beyond facilities — it's about empowering communities and strengthening public health for the long term.

Engineering a new era of American innovation

The details:

• Gilead is harnessing AI and automation to transform how medicines are discovered, manufactured, and delivered — faster, smarter and more safely.
• Next-generation facilities in California will be equipped with predictive analytics, digital monitoring and autonomous robotics.
• Designed in collaboration with Bay Area tech startups, these facilities set a new standard for biopharma infrastructure and speed — from groundbreaking to completion in under two years.

With more than $5 billion invested in facilities that map the flow of scientific innovation — from research to clinical manufacturing — Gilead's campuses embody the speed and agility of our discoveries.

Building resilience through science

Plus, plus, plus: During COVID-19, Gilead's U.S.-anchored supply chain ensured uninterrupted global access to essential treatments.

With the majority of our workforce and intellectual property based in the U.S. — and a global footprint spanning 70 sites across 38 countries — they're building a system that can adapt, shift and scale in real time. Strategic redundancy, flexible manufacturing and proven partnerships make our network a cornerstone of health security.

A global commitment, rooted at home

Worth a mention: While expanding its U.S. footprint, Gilead continues to invest in research, manufacturing and partnerships abroad. A globally integrated model ensures patients everywhere benefit from discoveries made at home.

Whether scaling a COVID-19 antiviral across continents or sourcing ingredients for personalized therapies, Gilead's global operations balance efficiency with equity — and keep patients at the center of everything they do.

Learn more.